Intangible Assets

12 Months Ended

Jun. 30, 2021

Intangible Assets

Note 5. Intangible Assets

Intangible assets consisted of the following, in thousands:

	June 30,
	2021			2020
S*Bio Patents—Gross	$	273		$	273
Less: accumulated amortization		(273	)		(273	)
Intangible assets, net	$	—		$	—

Amortization expense of intangible assets for the years ended June 30, 2021, 2020 and 2019 was zero, $34,000, and $35,000, respectively. As a result of Helsinn discontinuing the Phase 3 study of pracinostat in AML, during the year ended June 30, 2020, we assessed the estimated future cash flows associated with the patents acquired from S*Bio and recorded an impairment charge of $0.2 million to write off the remaining book value of the intangible assets.